BioNTech is building a state-of-the-art production facility with the goal to manufacture mRNA-based cancer immunotherapies at clinical and, potentially, at commercial scale. Valeska Schilling, Plant and Project Manager at BioNTech’s Mainz site, offers a personal perspective on her work and explains how the company intends to leverage this state-of-the-art facility to advance cancer treatment.
By making this investment, BioNTech is taking another step toward the future production of innovative cancer therapies in Mainz. The technology aims to activate the immune system to recognize and attack cancer cells.
The team in Mainz is prepared to transition to commercial-scale production if approval is granted, marking a significant milestone in the development of novel approaches to cancer treatment.
»What motivates me is that we are creating the infrastructure for an innovative approach to treatment.«
Valeska Schilling, Plant and Project Manager at BioNTech’s Mainz site
